Russell Investments Group
PTGX icon

Russell Investments Group’s Protagonist Therapeutics PTGX Stock Holding History

Russell Investments Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
115,425
+75,049
+186% +$7.84M 0.01% 892
2026
Q1 		$4.26M Buy
40,376
+34,653
+606% +$3.07M ﹤0.01% 1445
2025
Q4 		$500K Sell
5,723
-201
-3% -$16.5K ﹤0.01% 2497
2025
Q3 		$394K Buy
5,924
+5,795
+4,492% +$329K ﹤0.01% 2574
2025
Q2 		$7.13K Sell
129
-3,229
-96% -$155K ﹤0.01% 3388
2025
Q1 		$162K Buy
3,358
+3,329
+11,479% +$139K ﹤0.01% 2648
2024
Q4 		$1.12K Buy
29
+5
+21% +$218 ﹤0.01% 3515
2024
Q3 		$1.08K Sell
24
-1,192
-98% -$48.2K ﹤0.01% 3472
2024
Q2 		$42.1K Hold
1,216
– – ﹤0.01% 2801
2024
Q1 		$35.2K Buy
+1,216
New +$33.1K ﹤0.01% 2708
2023
Q4 		– Sell
-12
Closed -$200 – 3288
2023
Q3 		$200 Sell
12
-43,510
-100% -$844K ﹤0.01% 3497
2023
Q2 		$1.2M Sell
43,522
-56,564
-57% -$1.42M ﹤0.01% 1840
2023
Q1 		$2.3M Sell
100,086
-98,883
-50% -$1.66M ﹤0.01% 1496
2022
Q4 		$2.17M Sell
198,969
-31,878
-14% -$269K ﹤0.01% 1542
2022
Q3 		$1.94M Sell
230,847
-58,715
-20% -$556K ﹤0.01% 1562
2022
Q2 		$2.29M Buy
289,562
+106,446
+58% +$1.29M ﹤0.01% 1511
2022
Q1 		$4.33M Buy
183,116
+19,527
+12% +$550K 0.01% 1241
2021
Q4 		$5.59M Buy
163,589
+86,587
+112% +$2.74M 0.01% 1184
2021
Q3 		$1.36M Buy
77,002
+22,998
+43% +$980K ﹤0.01% 2049
2021
Q2 		$2.42M Buy
54,004
+3,271
+6% +$108K ﹤0.01% 1790
2021
Q1 		$1.31M Sell
50,733
-4,327
-8% -$110K ﹤0.01% 2122
2020
Q4 		$1.11M Sell
55,060
-51,292
-48% -$1.1M ﹤0.01% 2075
2020
Q3 		$2.08M Sell
106,352
-75,384
-41% -$1.41M ﹤0.01% 1661
2020
Q2 		$3.21M Buy
181,736
+77,296
+74% +$970K 0.01% 1361
2020
Q1 		$736K Buy
104,440
+56,872
+120% +$426K ﹤0.01% 1994
2019
Q4 		$334K Sell
47,568
-29,267
-38% -$291K ﹤0.01% 2537
2019
Q3 		$926K Buy
+76,835
New +$968K ﹤0.01% 2038
2018
Q4 		– Sell
-5,900
Closed -$61K – 3014
2018
Q3 		$61K Buy
+5,900
New +$50.8K ﹤0.01% 2811

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

Russell Investments Group's PTGX Position: Q2 2026 in Review

Russell Investments Group increased its Protagonist Therapeutics (PTGX) stake by 186% in Q2 2026, buying an estimated $7.84M and bringing the position to 115,425 shares worth $14.1M. The position accounts for 0.01% of the portfolio, ranked #892.

Russell Investments Group first reported a position in PTGX in Q3 2018 and has held it in 28 quarters since. 143 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Russell Investments Group held 115,425 shares of Protagonist Therapeutics worth $14.1M as of Q2 2026.
  • Russell Investments Group bought 75,049 Protagonist Therapeutics shares in Q2 2026, an estimated $7.84M.
  • Protagonist Therapeutics made up 0.01% of Russell Investments Group's portfolio in Q2 2026, its #892 holding.
  • Russell Investments Group first reported a position in Protagonist Therapeutics in Q3 2018 and has held it in 28 quarters since.
  • 143 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.